Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
- Status
- COMPLETED
- Phase
- PHASE2
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
- Status
- COMPLETED
- Phase
- PHASE2
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2